Author

A. Lefevre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:metagenomics· 1

Frequent Co-Authors

A. Girault· 1 shared A. J. Garcia-Saez· 1 shared A. Le Pape· 1 shared A. Petit-Paitel· 1 shared A. Robert· 1 shared A.-S. Gay· 1 shared B. Madji Hounoum· 1 shared C. Vandier· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Girault

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multiomics study of CHCHD10S59L-related disease reveals energy metabolism downregulation: OXPHOS and beta-oxidation deficiencies associated with lipids alterations

B. Madji Hounoum, R. Bellon, E. C. Genin, S. Bannwarth, A. Lefevre, L. Fleuriol, D. Debayle, A.-S. Gay, A. Petit-Paitel, S. Lacas-Gervais, H. Blasco, P. Edmond, V. Paquis-Flucklinger, J.-E. RICCI

This study identifies metabolic and lipid alterations in CHCHD10S59L-related disease, showing OXPHOS and beta-oxidation deficiencies and suggesting L-acetylcarnitine as a potential therapeutic.

bioRxiv · Jan 19, 2023 · PreprintCell Biology

Curcumin and NCLX Inhibitors Share Anti-Tumoral Mechanisms in Microsatellite-Instability-Driven Colorectal Cancer

M. Gueguinou, S. Ibrahim, J. Bourgeais, A. Robert, T. Pathak, X. Zhang, D. Crottes, J. Dupuy, D. Ternant, V. Monbet, R. Guibon, H. Flores-Romero, A. Lefevre, S. Lerondel, A. Le Pape, , T. Lecomte

This study identifies NCLX as a therapeutic target in MSI-driven CRC, showing that curcumin and NCLX inhibitors induce anti-tumoral effects through mitochondrial calcium overload and apoptosis.

bioRxiv · Jan 18, 2022Cancer Biology